Cargando…

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ping, Liu, Yang, Liang, Yun, Bo, Jian, Gao, Sujun, Hu, Yongxian, Hu, Yu, Huang, He, Huang, Xiaojun, Jing, Hongmei, Ke, Xiaoyan, Li, Jianyong, Li, Yuhua, Liu, Qifa, Lu, Peihua, Mei, Heng, Niu, Ting, Song, Yongping, Song, Yuqin, Su, Liping, Tu, Sanfang, Wang, Jianxiang, Wu, Depei, Wang, Zhao, Xu, Kailin, Ying, Zhitao, Yang, Qingming, Zhang, Yajing, Shi, Fengxia, Zhang, Bin, Zhang, Huilai, Zhang, Xi, Zhao, Mingfeng, Zhao, Weili, Zhao, Xiangyu, Huang, Liang, Zhu, Jun, Qian, Wenbin, Han, Weidong, Liang, Aibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978889/
https://www.ncbi.nlm.nih.gov/pubmed/36861439
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585
_version_ 1784899619584475136
author Li, Ping
Liu, Yang
Liang, Yun
Bo, Jian
Gao, Sujun
Hu, Yongxian
Hu, Yu
Huang, He
Huang, Xiaojun
Jing, Hongmei
Ke, Xiaoyan
Li, Jianyong
Li, Yuhua
Liu, Qifa
Lu, Peihua
Mei, Heng
Niu, Ting
Song, Yongping
Song, Yuqin
Su, Liping
Tu, Sanfang
Wang, Jianxiang
Wu, Depei
Wang, Zhao
Xu, Kailin
Ying, Zhitao
Yang, Qingming
Zhang, Yajing
Shi, Fengxia
Zhang, Bin
Zhang, Huilai
Zhang, Xi
Zhao, Mingfeng
Zhao, Weili
Zhao, Xiangyu
Huang, Liang
Zhu, Jun
Qian, Wenbin
Han, Weidong
Liang, Aibin
author_facet Li, Ping
Liu, Yang
Liang, Yun
Bo, Jian
Gao, Sujun
Hu, Yongxian
Hu, Yu
Huang, He
Huang, Xiaojun
Jing, Hongmei
Ke, Xiaoyan
Li, Jianyong
Li, Yuhua
Liu, Qifa
Lu, Peihua
Mei, Heng
Niu, Ting
Song, Yongping
Song, Yuqin
Su, Liping
Tu, Sanfang
Wang, Jianxiang
Wu, Depei
Wang, Zhao
Xu, Kailin
Ying, Zhitao
Yang, Qingming
Zhang, Yajing
Shi, Fengxia
Zhang, Bin
Zhang, Huilai
Zhang, Xi
Zhao, Mingfeng
Zhao, Weili
Zhao, Xiangyu
Huang, Liang
Zhu, Jun
Qian, Wenbin
Han, Weidong
Liang, Aibin
author_sort Li, Ping
collection PubMed
description Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.
format Online
Article
Text
id pubmed-9978889
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Compuscript
record_format MEDLINE/PubMed
spelling pubmed-99788892023-03-03 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma Li, Ping Liu, Yang Liang, Yun Bo, Jian Gao, Sujun Hu, Yongxian Hu, Yu Huang, He Huang, Xiaojun Jing, Hongmei Ke, Xiaoyan Li, Jianyong Li, Yuhua Liu, Qifa Lu, Peihua Mei, Heng Niu, Ting Song, Yongping Song, Yuqin Su, Liping Tu, Sanfang Wang, Jianxiang Wu, Depei Wang, Zhao Xu, Kailin Ying, Zhitao Yang, Qingming Zhang, Yajing Shi, Fengxia Zhang, Bin Zhang, Huilai Zhang, Xi Zhao, Mingfeng Zhao, Weili Zhao, Xiangyu Huang, Liang Zhu, Jun Qian, Wenbin Han, Weidong Liang, Aibin Cancer Biol Med Consensus Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS. Compuscript 2023-02-15 2023-03-02 /pmc/articles/PMC9978889/ /pubmed/36861439 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585 Text en Copyright: © 2023, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Consensus
Li, Ping
Liu, Yang
Liang, Yun
Bo, Jian
Gao, Sujun
Hu, Yongxian
Hu, Yu
Huang, He
Huang, Xiaojun
Jing, Hongmei
Ke, Xiaoyan
Li, Jianyong
Li, Yuhua
Liu, Qifa
Lu, Peihua
Mei, Heng
Niu, Ting
Song, Yongping
Song, Yuqin
Su, Liping
Tu, Sanfang
Wang, Jianxiang
Wu, Depei
Wang, Zhao
Xu, Kailin
Ying, Zhitao
Yang, Qingming
Zhang, Yajing
Shi, Fengxia
Zhang, Bin
Zhang, Huilai
Zhang, Xi
Zhao, Mingfeng
Zhao, Weili
Zhao, Xiangyu
Huang, Liang
Zhu, Jun
Qian, Wenbin
Han, Weidong
Liang, Aibin
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
title 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
title_full 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
title_fullStr 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
title_full_unstemmed 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
title_short 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
title_sort 2022 chinese expert consensus and guidelines on clinical management of toxicity in anti-cd19 chimeric antigen receptor t-cell therapy for b-cell non-hodgkin lymphoma
topic Consensus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978889/
https://www.ncbi.nlm.nih.gov/pubmed/36861439
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0585
work_keys_str_mv AT liping 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT liuyang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT liangyun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT bojian 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT gaosujun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT huyongxian 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT huyu 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT huanghe 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT huangxiaojun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT jinghongmei 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT kexiaoyan 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT lijianyong 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT liyuhua 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT liuqifa 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT lupeihua 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT meiheng 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT niuting 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT songyongping 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT songyuqin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT suliping 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT tusanfang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT wangjianxiang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT wudepei 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT wangzhao 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT xukailin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT yingzhitao 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT yangqingming 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhangyajing 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT shifengxia 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhangbin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhanghuilai 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhangxi 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhaomingfeng 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhaoweili 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhaoxiangyu 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT huangliang 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT zhujun 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT qianwenbin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT hanweidong 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma
AT liangaibin 2022chineseexpertconsensusandguidelinesonclinicalmanagementoftoxicityinanticd19chimericantigenreceptortcelltherapyforbcellnonhodgkinlymphoma